Article Versions Notes

Silva G, Sales-Dias J, Casal D, Alves S, Domenici G, Barreto C, Matos C, Lemos AR, Matias AT, Kucheryava K, et al. Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer. Cancers. 2021; 13(16):4074. https://doi.org/10.3390/cancers13164074

Silva, Gabriela, Joana Sales-Dias, Diogo Casal, Sara Alves, Giacomo Domenici, Clara Barreto, Carolina Matos, Ana R. Lemos, Ana T. Matias, Khrystyna Kucheryava, and et al. 2021. "Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer" Cancers 13, no. 16: 4074. https://doi.org/10.3390/cancers13164074

Silva, G., Sales-Dias, J., Casal, D., Alves, S., Domenici, G., Barreto, C., Matos, C., Lemos, A. R., Matias, A. T., Kucheryava, K., Ferreira, A., Moita, M. R., Braga, S., Brito, C., Cabral, M. G., Casalou, C., Barral, D. C., Sousa, P. M. F., Videira, P. A., ... Barbas, A. (2021). Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer. Cancers, 13(16), 4074. https://doi.org/10.3390/cancers13164074